Skip to main navigation Skip to search Skip to main content

Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma

  • Rosa Peltrini
  • , Rebecca L. Cordell
  • , Michael Wilde
  • , Shahd Abuhelal
  • , Eleanor Quek
  • , Nazanin Zounemat-Kermani
  • , Wadah Ibrahim
  • , Matthew Richardson
  • , Paul Brinkman
  • , Florence Schleich
  • , Pierre Hugues Stefanuto
  • , Hnin Aung
  • , Neil Greening
  • , Sven Erik Dahlen
  • , Ratko Djukanovic
  • , Ian M. Adcock
  • , Christopher Brightling
  • , Paul Monks
  • , Salman Siddiqui*
  • , on behalf of the EMBER EPSRC/MRC Consortium
  • and the U-BIOPRED-IMI Study Group
*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Rationale: Volatile organic compounds (VOCs) in asthmatic breath may be associated with sputum eosinophilia. We developed a volatile biomarker signature to predict sputum eosinophilia in asthma.

Methods
: VOCs emitted into the space above sputum samples (headspace) from patients with severe asthma (n = 36) were collected onto sorbent tubes and analyzed using thermal desorption gas chromatography-mass spectrometry (GC-MS). Elastic net regression identified stable VOCs associated with sputum eosinophilia  ⩾ 3% and generated a volatile biomarker signature. This VOC signature was validated in breath samples from: 1) patients with acute asthma according to blood eosinophilia  ⩾0.3 × 109cells/L or sputum eosinophilia of  ⩾3% in the UK EMBER (East Midlands Breathomics Pathology Node) consortium (n = 65) and 2) U-BIOPRED-IMI (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes Innovative Medicines Initiative) consortium (n = 42). Breath samples were collected onto sorbent tubes (EMBER) or Tedlar bags (U-BIOPRED) and analyzed by GC-MS (GC × GC-MS for EMBER or GC-MS for U-BIOPRED).

Measurements and Main Results
: The in vitro headspace identified 19 VOCs associated with sputum eosinophilia, and the derived VOC signature yielded good diagnostic accuracy for sputum eosinophilia  ⩾3% in headspace (area under the receiver operating characteristic curve [AUROC] 0.90; 95% confidence interval [CI], 0.80-0.99; P < 0.0001), correlated inversely with sputum eosinophil percentage (rs = -0.71; P < 0.0001), and outperformed fractional exhaled nitric oxide (AUROC 0.61; 95% CI, 0.35-0.86). Analysis of exhaled breath in replication cohorts yielded a VOC signature AUROC (95% CI) for acute asthma exacerbations of 0.89 (0.76-1.0) (EMBER cohort) with sputum eosinophilia and 0.90 (0.75-1.0) in U-BIOPRED, again outperforming fractional exhaled nitric oxide in U-BIOPRED (0.62 [0.33-0.90]).

Conclusions
: We have discovered and provided early-stage clinical validation of a volatile biomarker signature associated with eosinophilic airway inflammation. Further work is needed to translate our discovery using point-of-care clinical sensors.
Original languageEnglish
Pages (from-to)1101-1112
Number of pages12
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume210
Issue number9
DOIs
Publication statusPublished - 1 Nov 2024

Keywords

  • eosinophilic airway inflammation
  • severe asthma
  • volatile organic compound biomarkers

Fingerprint

Dive into the research topics of 'Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma'. Together they form a unique fingerprint.

Cite this